Finance

Lists
4503:TYO
Astellas Pharma Inc
Â¥2,699.00
+0.78%
(+21.00) 1D
Nov 13, 3:30:00 PM GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4503...
Open
Â¥2,688
High
Â¥2,712
Low
Â¥2,668
Mkt. cap
4.88T
Avg. vol.
6.05M
Volume
5.55M
Dividend
2.93%
Quarterly dividend
Â¥20
Ex-dividend date
Mar 30, 2027
P/E ratio
12.56
52-wk high
Â¥2,753
52-wk low
Â¥1,851
EPS
Â¥215
Shares outstanding
1.92B
No. of employees
14K
Open
Â¥2,688
High
Â¥2,712
Low
Â¥2,668
Mkt. cap
4.88T
Avg. vol.
6.05M
Volume
5.55M
Dividend
2.93%
Quarterly dividend
Â¥20
Ex-dividend date
Mar 30, 2027
P/E ratio
12.56
52-wk high
Â¥2,753
52-wk low
Â¥1,851
EPS
Â¥215
Shares outstanding
1.92B
No. of employees
14K
News stories
From web sources and news partners
Profile
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd. Astellas is a member of the Mitsubishi UFJ Financial Group keiretsu. Wikipedia
About Astellas Pharma Inc
CEONaoki Okamura
Employees14.1K
FoundedApr 1, 2005
HeadquartersChuo City, Tokyo, Japan
SectorHealth Care
IndustryPharmaceutical industry
Last report
Nov 4, 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (JPY)
629.95B / 594.09B
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
554.57B
537.92B
640.91B
629.95B
Cost of goods sold
104.03B
93.67B
122.70B
125.16B
Cost of revenue
104.03B
93.67B
122.70B
125.16B
Research and development expenses
85.77B
95.94B
81.73B
85.99B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
228.24B
234.70B
215.07B
215.29B
Operating expense
358.98B
336.48B
332.86B
372.20B
Total operating expenses
463.01B
430.14B
455.56B
497.35B
Operating income
91.55B
107.78B
185.35B
132.59B
Other non operating income
1.50M
-241.00M
1.00M
-
EBT including unusual items
90.99B
48.02B
186.51B
130.94B
EBT excluding unusual items
90.82B
113.57B
186.51B
130.94B
Income tax expense
19.02B
4.41B
44.76B
31.16B
Effective tax rate
20.90%
9.18%
24.00%
23.80%
Other operating expenses
9.72B
-29.93B
388.00M
35.31B
Net income
71.95B
43.52B
141.83B
99.85B
Net profit margin
12.97%
8.09%
22.13%
15.85%
Earnings per share
-
-
-
-
Interest and investment income
2.10B
1.29B
5.13B
2.72B
Interest expense
-2.74B
-
-3.12B
-3.84B
Net interest expenses
-637.00M
1.29B
2.01B
-1.11B
Depreciation and amortization charges
-
35.76B
-
-35.67B
EBITDA
141.30B
158.14B
235.24B
182.02B
Gain or loss from assets sale
-
31.51B
-
29.78B
Upcoming events
AI content may include mistakes. Learn more
Google apps